Literature DB >> 34671130

Prognostic role of tumour-infiltrating lymphocytes and macrophages in relation to MSI, CDX2 and BRAF status: a population-based study of metastatic colorectal cancer patients.

Kristine Aasebø1, Jarle Bruun2, Christian H Bergsland2,3, Luís Nunes4, Geir Egil Eide5,6, Per Pfeiffer7, Olav Dahl8,9, Bengt Glimelius4, Ragnhild A Lothe2,3, Halfdan Sorbye8,9.   

Abstract

BACKGROUND: Tumour-infiltrating CD3, CD8 lymphocytes and CD68 macrophages are associated with favourable prognosis in localised colorectal cancer, but the effect in metastatic colorectal cancer (mCRC) is not established.
METHODS: A Scandinavian population-based cohort of non-resectable mCRC patients was studied. Tissue microarrays (n = 460) were stained with CD3, CD8 and CD68 using fluorescence-based multiplex immunohistochemistry. Associations with clinicopathological variables, overall survival (OS) and progression-free survival were estimated.
RESULTS: Two-thirds of microsatellite instable (MSI) and one-fourth of microsatellite stable (MSS) tumours displayed the highest quartile density of CD8. For CD3 high vs low cases, median OS was 20 vs 16 months (HR: 0.76, 95% CI: 0.59, 0.76, p = 0.025) with 3-year OS of 27 vs 13%. For CD68 high vs low cases, median OS was 23 vs 15 months (HR: 0.69, 95% CI: 0.54, 0.88, p = 0.003) with 3-year OS of 28 vs 12%. MSI, BRAF mutation and CDX2 loss were negative prognostic markers independent of tumour immune infiltration.
CONCLUSIONS: In mCRC, high lymphocyte infiltration was found in proportions of MSI and MSS tumours-potential subgroups of immunotherapy response. Tumour-infiltrating CD3 lymphocytes and CD68 macrophages were associated with median and long-term survival. MSI was a significant negative prognostic marker despite high immunogenicity.
© 2021. The Author(s), under exclusive licence to Springer Nature Limited.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 34671130      PMCID: PMC8727629          DOI: 10.1038/s41416-021-01586-5

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   9.075


  46 in total

1.  Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer.

Authors:  Thierry André; Kai-Keen Shiu; Tae Won Kim; Benny Vittrup Jensen; Lars Henrik Jensen; Cornelis Punt; Denis Smith; Rocio Garcia-Carbonero; Manuel Benavides; Peter Gibbs; Christelle de la Fouchardiere; Fernando Rivera; Elena Elez; Johanna Bendell; Dung T Le; Takayuki Yoshino; Eric Van Cutsem; Ping Yang; Mohammed Z H Farooqui; Patricia Marinello; Luis A Diaz
Journal:  N Engl J Med       Date:  2020-12-03       Impact factor: 91.245

Review 2.  The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy.

Authors:  Jonathan J Havel; Diego Chowell; Timothy A Chan
Journal:  Nat Rev Cancer       Date:  2019-03       Impact factor: 60.716

3.  PD-1 Blockade in Tumors with Mismatch-Repair Deficiency.

Authors:  Dung T Le; Jennifer N Uram; Hao Wang; Bjarne R Bartlett; Holly Kemberling; Aleksandra D Eyring; Andrew D Skora; Brandon S Luber; Nilofer S Azad; Dan Laheru; Barbara Biedrzycki; Ross C Donehower; Atif Zaheer; George A Fisher; Todd S Crocenzi; James J Lee; Steven M Duffy; Richard M Goldberg; Albert de la Chapelle; Minori Koshiji; Feriyl Bhaijee; Thomas Huebner; Ralph H Hruban; Laura D Wood; Nathan Cuka; Drew M Pardoll; Nickolas Papadopoulos; Kenneth W Kinzler; Shibin Zhou; Toby C Cornish; Janis M Taube; Robert A Anders; James R Eshleman; Bert Vogelstein; Luis A Diaz
Journal:  N Engl J Med       Date:  2015-05-30       Impact factor: 91.245

Review 4.  The immune contexture in cancer prognosis and treatment.

Authors:  Wolf H Fridman; Laurence Zitvogel; Catherine Sautès-Fridman; Guido Kroemer
Journal:  Nat Rev Clin Oncol       Date:  2017-07-25       Impact factor: 66.675

5.  The vigorous immune microenvironment of microsatellite instable colon cancer is balanced by multiple counter-inhibitory checkpoints.

Authors:  Nicolas J Llosa; Michael Cruise; Ada Tam; Elizabeth C Wicks; Elizabeth M Hechenbleikner; Janis M Taube; Richard L Blosser; Hongni Fan; Hao Wang; Brandon S Luber; Ming Zhang; Nickolas Papadopoulos; Kenneth W Kinzler; Bert Vogelstein; Cynthia L Sears; Robert A Anders; Drew M Pardoll; Franck Housseau
Journal:  Cancer Discov       Date:  2014-10-30       Impact factor: 39.397

6.  Multicenter International Society for Immunotherapy of Cancer Study of the Consensus Immunoscore for the Prediction of Survival and Response to Chemotherapy in Stage III Colon Cancer.

Authors:  Bernhard Mlecnik; Carlo Bifulco; Gabriela Bindea; Florence Marliot; Alessandro Lugli; J Jack Lee; Inti Zlobec; Tilman T Rau; Martin D Berger; Iris D Nagtegaal; Elisa Vink-Börger; Arndt Hartmann; Carol Geppert; Julie Kolwelter; Susanne Merkel; Robert Grützmann; Marc Van den Eynde; Anne Jouret-Mourin; Alex Kartheuser; Daniel Léonard; Christophe Remue; Julia Y Wang; Prashant Bavi; Michael H A Roehrl; Pamela S Ohashi; Linh T Nguyen; SeongJun Han; Heather L MacGregor; Sara Hafezi-Bakhtiari; Bradly G Wouters; Giuseppe V Masucci; Emilia K Andersson; Eva Zavadova; Michal Vocka; Jan Spacek; Lubos Petruzelka; Bohuslav Konopasek; Pavel Dundr; Helena Skalova; Kristyna Nemejcova; Gerardo Botti; Fabiana Tatangelo; Paolo Delrio; Gennaro Ciliberto; Michele Maio; Luigi Laghi; Fabio Grizzi; Tessa Fredriksen; Bénédicte Buttard; Lucie Lafontaine; Daniela Bruni; Anastasia Lanzi; Carine El Sissy; Nacilla Haicheur; Amos Kirilovsky; Anne Berger; Christine Lagorce; Christopher Paustian; Carmen Ballesteros-Merino; Jeroen Dijkstra; Carlijn van de Water; Shannon van Lent-van Vliet; Nikki Knijn; Ana-Maria Muşină; Dragos-Viorel Scripcariu; Boryana Popivanova; Mingli Xu; Tomonobu Fujita; Shoichi Hazama; Nobuaki Suzuki; Hiroaki Nagano; Kiyotaka Okuno; Toshihiko Torigoe; Noriyuki Sato; Tomohisa Furuhata; Ichiro Takemasa; Kyogo Itoh; Prabhu S Patel; Hemangini H Vora; Birva Shah; Jayendrakumar B Patel; Kruti N Rajvik; Shashank J Pandya; Shilin N Shukla; Yili Wang; Guanjun Zhang; Yutaka Kawakami; Francesco M Marincola; Paolo A Ascierto; Bernard A Fox; Franck Pagès; Jérôme Galon
Journal:  J Clin Oncol       Date:  2020-09-08       Impact factor: 44.544

Review 7.  Immune escape mechanisms in colorectal cancer pathogenesis and liver metastasis.

Authors:  Massimo Pancione; Guido Giordano; Andrea Remo; Antonio Febbraro; Lina Sabatino; Erminia Manfrin; Michele Ceccarelli; Vittorio Colantuoni
Journal:  J Immunol Res       Date:  2014-01-16       Impact factor: 4.818

8.  Prediction of overall survival in stage II and III colon cancer beyond TNM system: a retrospective, pooled biomarker study.

Authors:  R Dienstmann; M J Mason; F A Sinicrope; A I Phipps; S Tejpar; A Nesbakken; S A Danielsen; A Sveen; D D Buchanan; M Clendenning; C Rosty; B Bot; S R Alberts; J Milburn Jessup; R A Lothe; M Delorenzi; P A Newcomb; D Sargent; J Guinney
Journal:  Ann Oncol       Date:  2017-05-01       Impact factor: 32.976

9.  Survival of patients with deficient mismatch repair metastatic colorectal cancer in the pre-immunotherapy era.

Authors:  G Emerens Wensink; Marloes A G Elferink; Anne M May; Linda Mol; Patricia A H Hamers; Sandra D Bakker; Geert-Jan Creemers; Jan Willem B de Groot; Gerty J de Klerk; Brigitte C M Haberkorn; Annebeth W Haringhuizen; Ronald Hoekstra; J Cornelis B Hunting; Emile D Kerver; Danielle Mathijssen-van Stein; Marco B Polée; Johannes F M Pruijt; Patricia Quarles van Ufford-Mannesse; Sandra Radema; Ronald C Rietbroek; Lieke H J Simkens; Bea C Tanis; Daan Ten Bokkel Huinink; Manuel L R Tjin-A-Ton; Cathrien S Tromp-van Driel; Monique M Troost; Agnes J van de Wouw; Franchette W P J van den Berkmortel; Anke J M van der Pas; Ankie M T van der Velden; Marjan A van Dijk; Joyce M van Dodewaard-de Jong; Edith B van Druten; Theo van Voorthuizen; Gerrit Jan Veldhuis; Henk M W Verheul; Hanneke J H M J Vestjens; Jeroen Vincent; Onno W Kranenburg; Cornelis J A Punt; Geraldine R Vink; Jeanine M L Roodhart; Miriam Koopman
Journal:  Br J Cancer       Date:  2020-10-13       Impact factor: 7.640

10.  CD8+ tumor-infiltrating lymphocytes within the primary tumor of patients with synchronous de novo metastatic colorectal carcinoma do not track with survival.

Authors:  Rosemary Millen; Shona Hendry; Vignesh Narasimhan; Rebecca Abbott; Matthew Croxford; Peter Gibbs; Jeanne Tie; Hui-Li Wong; Ian Jones; Suzanne Kosmider; David Byrne; John Zalcberg; Stephen Fox; Jayesh Desai; Kumar Visvanathan; Robert G Ramsay; Ben Tran
Journal:  Clin Transl Immunology       Date:  2020-07-17
View more
  1 in total

1.  Prognostic factors of BRAF V600E colorectal cancer with liver metastases: a retrospective multicentric study.

Authors:  Sahir Javed; Stéphane Benoist; Patrick Devos; Stéphanie Truant; Rosine Guimbaud; Astrid Lièvre; David Sefrioui; Romain Cohen; Pascal Artru; Aurélien Dupré; Jean-Baptiste Bachet; Christelle de la Fouchardière; Anne Ploquin; Anthony Turpin
Journal:  World J Surg Oncol       Date:  2022-04-23       Impact factor: 3.253

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.